Correction to: Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug–Drug Interactions.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Works matching IS 03125963 AND DT 2022 AND VI 61 AND IP 3
Results: 11
1
2
Drug–Drug Interaction Potential with Once-Weekly Isoniazid/Rifapentine (3HP) for the Treatment of Latent Tuberculosis Infection.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 339, doi. 10.1007/s40262-021-01098-8
- By:
- Publication type:
- Article
3
Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 347, doi. 10.1007/s40262-021-01095-x
- By:
- Publication type:
- Article
4
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 363, doi. 10.1007/s40262-021-01088-w
- By:
- Publication type:
- Article
5
Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 413, doi. 10.1007/s40262-021-01084-0
- By:
- Publication type:
- Article
6
Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
- Published in:
- 2022
- By:
- Publication type:
- journal article
7
Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 439, doi. 10.1007/s40262-021-01082-2
- By:
- Publication type:
- Article
8
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 423, doi. 10.1007/s40262-021-01081-3
- By:
- Publication type:
- Article
9
Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 401, doi. 10.1007/s40262-021-01076-0
- By:
- Publication type:
- Article
10
Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 387, doi. 10.1007/s40262-021-01071-5
- By:
- Publication type:
- Article
11
Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.
- Published in:
- Clinical Pharmacokinetics, 2022, v. 61, n. 3, p. 375, doi. 10.1007/s40262-021-01067-1
- By:
- Publication type:
- Article